RAPT

0.8254

2.18% 0.0176

Handel nachbörslich: .81 -0.0154 -1.87%

Rapt Therapeutics Inc (RAPT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$0.8078

Offen:

$0.8

24-Stunden-Volumen:

703.29K

Relative Volume:

1.30

Marktkapitalisierung:

$28.85M

Einnahmen:

$3.25M

Nettoeinkommen (Verlust:

$-116.80M

KGV:

-0.3068

EPS:

-2.69

Netto-Cashflow:

$-98.17M

1W Leistung:

-9.30%

1M Leistung:

-22.86%

6M Leistung:

-73.29%

1J Leistung:

-96.12%

1-Tages-Spanne:

$0.80

$0.8782

1-Wochen-Bereich:

$0.7893

$0.9648

52-Wochen-Spanne:

$0.7893

$27.35

Rapt Therapeutics Inc Stock (RAPT) Company Profile

Firmenname

Rapt Therapeutics Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

(650) 489-9000

Adresse

561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

RAPT's Discussions on Twitter

Vergleichen Sie RAPT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RAPT Rapt Therapeutics Inc	0.8254	28.85M	3.25M	-116.80M	-98.17M	-3.05
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-13	Herabstufung	Stifel	Buy → Hold
2024-11-11	Herabstufung	JP Morgan	Neutral → Underweight
2024-11-11	Herabstufung	Piper Sandler	Overweight → Neutral
2024-05-14	Herabstufung	Wolfe Research	Outperform → Peer Perform
2024-05-10	Herabstufung	Barclays	Overweight → Equal Weight
2024-05-10	Herabstufung	Guggenheim	Buy → Neutral
2024-02-22	Herabstufung	UBS	Buy → Neutral
2024-02-21	Herabstufung	H.C. Wainwright	Buy → Neutral
2024-02-21	Herabstufung	JP Morgan	Overweight → Neutral
2024-02-21	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-02-20	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2024-02-16	Eingeleitet	Evercore ISI	Outperform
2024-02-15	Eingeleitet	Wolfe Research	Outperform
2023-09-14	Eingeleitet	Berenberg	Buy
2023-08-09	Eingeleitet	Stifel	Buy
2023-06-15	Eingeleitet	Barclays	Overweight
2023-01-04	Eingeleitet	Guggenheim	Buy
2022-12-01	Eingeleitet	Goldman	Buy
2022-09-21	Eingeleitet	CapitalOne	Overweight
2022-05-24	Fortgesetzt	Cantor Fitzgerald	Overweight
2021-12-09	Eingeleitet	JP Morgan	Overweight
2021-08-12	Eingeleitet	SVB Leerink	Outperform
2021-06-21	Eingeleitet	Piper Sandler	Overweight
2020-06-01	Eingeleitet	H.C. Wainwright	Buy
2020-05-19	Eingeleitet	Cantor Fitzgerald	Overweight
2020-04-13	Eingeleitet	ROTH Capital	Buy
2019-11-25	Eingeleitet	BMO Capital Markets	Outperform
2019-11-25	Eingeleitet	UBS	Buy
2019-11-25	Eingeleitet	Wells Fargo	Outperform

Alle ansehen

Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten

Dec 20, 2024

Charles Schwab Investment Management Inc. Cuts Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

Dec 20, 2024

Dec 15, 2024

Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings? - MSN

Dec 15, 2024

Dec 13, 2024

RAPT Therapeutics stock plunges to 52-week low of $0.92 - Investing.com India

Dec 13, 2024

RAPT Therapeutics' SWOT analysis: stock faces challenges amid pipeline setbacks - Investing.com

Dec 13, 2024

Dec 06, 2024

RAPT Therapeutics stock plunges to 52-week low of $1 By Investing.com - Investing.com South Africa

Dec 06, 2024

RAPT Therapeutics stock plunges to 52-week low of $1 - Investing.com

Dec 06, 2024

Nov 28, 2024

HC Wainwright Has Optimistic Outlook of RAPT FY2024 Earnings - Defense World

Nov 28, 2024

Nov 27, 2024

HC Wainwright Reaffirms “Neutral” Rating for RAPT Therapeutics (NASDAQ:RAPT) - Defense World

Nov 27, 2024

Nov 20, 2024

RAPT scraps zelnecirnon program, stock plunges 46% (update) - MSN

Nov 20, 2024

RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - MSN

Nov 20, 2024

Nov 18, 2024

RAPT Therapeutics stock plunges to 52-week low of $1.11 By Investing.com - Investing.com UK

Nov 18, 2024

Nov 17, 2024

RAPT Therapeutics announces option repricing to retain talent By Investing.com - Investing.com Nigeria

Nov 17, 2024

RAPT Therapeutics' SWOT analysis: biotech firm faces challenges, seeks new path - Investing.com Canada

Nov 14, 2024

Nov 13, 2024

RAPT Therapeutics Reports Improved Q3 2024 Results - TipRanks

Nov 13, 2024

RAPT Therapeutics' (RAPT) Hold Rating Reaffirmed at Stifel Nicolaus - MarketBeat

Nov 13, 2024

Nov 12, 2024

Wells Fargo & Company Has Lowered Expectations for RAPT Therapeutics (NASDAQ:RAPT) Stock Price - MarketBeat

Nov 12, 2024

RAPT Therapeutics (NASDAQ:RAPT) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Nov 12, 2024

RAPT Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 12, 2024

RAPT Therapeutics Narrows Q3 Loss by 41%, Cuts R&D Spend Amid Restructuring | RAPT Stock News - StockTitan

Nov 12, 2024

RAPT Therapeutics stock hits 52-week low at $1.49 By Investing.com - Investing.com Australia

Nov 12, 2024

RAPT Therapeutics stock hits 52-week low at $1.49 - Investing.com

Nov 12, 2024

Nov 11, 2024

Rapt Scraps Zelnecirnon, But Not Giving Up On CCR4 - Citeline News & Insights

Nov 11, 2024

Crude Oil Down 3%; Aramark Posts Upbeat Earnings - Benzinga

Nov 11, 2024

Nasdaq Moves Lower; Canaan Shares Surge - Benzinga

Nov 11, 2024

JPMorgan cuts Rapt Therapeutics to Underweight By Investing.com - Investing.com UK

Nov 11, 2024

JPMorgan Chase & Co. Downgrades RAPT Therapeutics (NASDAQ:RAPT) to Underweight - MarketBeat

Nov 11, 2024

U.S. Stock market: Binah Capital Group(+105.01%) and CERo Therapeutics(+152.00%) see strong gains, RAPT Therapeutics(−44.12%) declines during mid day trading - Business Upturn

Nov 11, 2024

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury - Benzinga

Nov 11, 2024

U.S. Stock market: RAPT Therapeutics drops 41% while CERo Therapeutics surges 136% in early trading - Business Upturn

Nov 11, 2024

Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results - Benzinga

Nov 11, 2024

Rapt Therapeutics Stops Development of Asthma, Atopic Dermatitis Drug Candidate After Reaction Sidelines Trials - MarketWatch

Nov 11, 2024

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury - The Manila Times

Nov 11, 2024

Based on Recent FDA Feedback RAPT Therapeutics Stops - GlobeNewswire

Nov 11, 2024

RAPT Therapeutics Halts Key Drug Program After FDA Safety Concerns, Liver Injury | RAPT Stock News - StockTitan

Nov 11, 2024

Contrasting RAPT Therapeutics (NASDAQ:RAPT) and Elanco Animal Health (NYSE:ELAN) - Defense World

Nov 11, 2024

Nov 10, 2024

Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth? - Simply Wall St

Nov 10, 2024

Nov 09, 2024

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky - Yahoo Finance

Nov 09, 2024

Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in RAPT Therapeutics Inc - GuruFocus.com

Nov 05, 2024

Oct 22, 2024

RAPT Therapeutics stock plunges to 52-week low of $1.65 By Investing.com - Investing.com Australia

Oct 22, 2024

Oct 21, 2024

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by Analysts - MarketBeat

Oct 21, 2024

RAPT Therapeutics stock plunges to 52-week low of $1.65 - Investing.com

Oct 21, 2024

Oct 10, 2024

RAPT stock touches 52-week low at $1.72 amid sharp yearly decline - Investing.com

Oct 10, 2024

Oct 04, 2024

Point72 Asset Management L.P. Acquires 706,900 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat

Oct 04, 2024

Oct 03, 2024